Molecular Pathology

Designed by pathologists and oncologists to create a better platform to diagnose and treat your patients.


What Is Molecular Pathology?

Molecular pathology is the study of molecules in a disease state. At CellNetix we utilize sensitive molecular tools that often confirm ambiguous diagnoses suspected by microscopic evaluation, guide therapeutic decisions and assess treatments. Molecular techniques can also assist with predicting the effectiveness of some important medications as well as identifying specific targets in individual patients’ tumors for new therapeutic modalities “personalized medicine”.

Featured Pathologist

Danbin Xu, MD, PhD. DABMG (Molecular Technical Director)

Dr. Xu is the Molecular Pathology Technical Director of Molecular Pathology at CellNetix. Prior to joining CellNetix in 2013, Dr Xu was director of the Molecular Diagnostics Lab at Providence Sacred Heart Medical Center in Spokane Washington where she designed and implemented their Next Generation Sequencing program as she has done at CellNetix. She is board certified in Clinical Molecular Genetics and received her medical training in Tianjin, China. She has also served and as program director and training director for the ABMG Clinical Molecular Genetics fellowship program.

Next-Generation Sequencing

NGS is similar in concept to traditional Sanger sequencing, where the bases of a given DNA fragment are sequentially identified through DNA re-synthesis. NGS extends this process in a massively parallel fashion across millions of reactions, rather than a limited number of DNA fragments. This significantly increases the coverage for variant calls, dramatically reduces the cost per gene per sample, and enables high throughput workflow for simultaneous screening of different types of mutations in many genes from multiple samples.


Our Symgene79 Panel

With the NEW Symgene79™ targeted gene panel, you can offer clients competitively priced, cutting-edge testing that isolates the 79 most actionable genes, for more relevant results, affordably delivered in weeks–not months. Learn more about Symgene here.


How Symgene79 NGS Works

Using the Illumina Miseq platform, an individual genomic DNA (gDNA) sample is first prepared into a library of small segments with adaptors and indexes attached. Indexed samples from multiple individuals are then pooled and loaded onto a single sequencing cartridge. Each fragment of the pooled samples is attached to the solid surface through the adaptor, and then uniformly and accurately sequenced in millions of parallel reactions. All variants are interpreted by our pathologists for clinical reference using publicly available databases and medical literature, and then used to create a concise and comprehensible report that can inform timely and appropriate clinical care for cancer patients.

Genes

AKT1 ALK APC ARAF ATM BCL2L11 BRAF
BRCA1 BRCA2 BTK CCND1 CDK4 CDK6 CDKN2A
CSF1R CTNNB1 DDR2 EGFR EPHA2 ERBB2 ERBB4
ESR1 FGFR1 FGFR2 FGFR3 FLT1 (VEGFR1) FLT3 FLT4
FOXL2 FYN GLI2 GNA11 GNAQ GNAS HDAC2
HRAS IGF1R JAK2 JAK3 KDR (VEGFR2) KIT KRAS
LCK LYN MAP2K1 (MEK1) MAP2K2 (MEK2) MDM2 MET MLH1
MSH2 MSH6 MST1R (RON) MTOR NOTCH1 NRAS NTRK2
PDGFRA PDGFRB PIK3CA PMS2 POLD1 POLE PTCH1
PTEN RAF1 RB1 RET ROS1 SMAD4 SMO
SRC STK11 TEK TERT TP53 TSC1 TSC2
VHL YES1

Understanding Your Bill

Find more information regarding our billing process and how we work with many different insurance carriers and their terms of coverage.
Click here for billing information.


Targeted Tumors

  • Thoracic Neoplasms
  • Breast and Ovarian Carcinomas
  • Colorectal Carcinoma
  • Melanoma
  • Gastrointestinal Tumor
  • Thyroid Carcinoma
  • Urothelial Carcinomas

Ordering Information

If you are not setup with an electronic interface for NGS testing, please contact your local representative or use the below requisition form and fax it to 206-215-5935 or 866-721-9697.

Requisition Form